Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Kazia Therapeutics Limited | Cantrixil | Ovarian cancer | Phase 2 | Intraperitoneal | Oncology | |
| Kazia Therapeutics Limited | Paxalisib (GDC-0084) with trastuzumab | Breast cancer brain metastases | Phase 2 | Oral with intravenous | Oncology | |
| Keros Therapeutics Inc. | Elritercept (KER-050) | Myelodysplastic syndromes (MDS) | Phase 3 | Trial Planned | Subcutaneous | Hematology |
| Keros Therapeutics Inc. | Elritercept - (RENEW) | Transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes | Phase 3 | Enrollment Initiation | Subcutaneous | Hematology |
| Keros Therapeutics Inc. | KER-047 | Iron deficiency anemia | Phase 2 | Trial Discontinued | oral | Anti-Anemia |
| Keros Therapeutics Inc. | Cibotercept (KER-012) - (TROPOS) | Pulmonary arterial hypertension (PAH) and disorders associated with bone loss | Phase 2 | Trial Discontinued | Subcutaneous | Respiratory |
| Keros Therapeutics Inc. | Elritercept with Ruxolitinib - (RESTORE) | Myelofibrosis | Phase 2 | Data Released | Subcutaneous | Hematology |
| Kezar Life Sciences Inc. | Zetomipzomib - (PALIZADE) | Lupus nephritis | Phase 2b | Trial Discontinued | Intravenous | Immunology |
